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CHAPTER 1 
INTRODUCTION 
1.1  Summary 
Normal human somatic cells have a limited proliferative potential when cultured 
in vitro before entering irreversible cell cycle arrest or senescence (1). In this process 
referred to as replicative senescence, cells permanently stop dividing and undergo 
genetic, biochemical and morphological changes. Cancer cells have developed the ability 
to overcome senescence and have an indefinite lifespan, sometimes referred to as 
immortal. This is an important step in the development of cancer in humans (2). Cellular 
immortalization is, therefore, the process of bypassing senescence to obtain a long, 
indefinite lifespan and develop the capacity to gain additional genetic and epigenetic 
mutations leading to tumor formation. Understanding of the genes, mechanisms and 
pathways that regulate the immortalization and senescence processes has provided 
information underlying abnormal cell proliferation and cancer.  
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1.2 Cellular senescence 
Cellular senescence was initially described as the Hayflick limit demonstrating 
that normal human cells had a limited ability to proliferate in culture (1). Cellular 
senescence appears to be one of the tumor suppressive mechanisms which is programmed 
to prevent cells from uncontrolled proliferation. Cellular senescence can be classified as 
replicative or induced (Figure 1). Replicative senescence refers to the internal clocking 
mechanism responding to the shortening of telomeres, the repetitive DNA sequence that 
caps the ends of chromosomes in cells (3). Shortening of telomere leads to loss of 
structural integrity of telomere nucleoproteins resulting in activation of the p53 and pRb 
tumor suppressor pathways and senescence (4). The second category of cellular 
senescence called induced or premature senescence results from exogenous factors 
including oxidative stress, DNA damage, and oncogene overexpression in normal cells 
(5-8). 
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Senescent cells are characterized by an irreversible growth arrest in G1 phase of 
the cell cycle, an enlarged and flat cell morphology; although metabolically active, they 
are unresponsive to mitotic signals. Senescent cells have alterations in gene expression 
including increased expression of cell cycle inhibitors such as p16INK4a and p21Cip1, the 
expression of senescence-associated-β-galactosidase at pH 6 (10, 11), and formation of 
senescent associated heterochromatic foci (SAHF) which coincides with the recruitment 
of heterochromatin proteins and the retinoblastoma (Rb) tumor suppressor for stable 
repression of E2F target genes (12). 
There are two stages that have been defined for cellular senescence: mortality 
stage 1 (M1) or senescence and morality stage 2 (M2) or crisis. When cells encounter the 
shortening of their telomeres, a DNA damage checkpoint triggers the activation of 
proteins responsible for arresting the cell cycle, including the tumor suppressor protein 
p53. The p16INK4a/pRb signaling pathway is another tumor suppressor pathway which is 
involved in regulating cell cycle arrest at the G1/S phase (12, 13). The inactivation of 
these tumor suppressor pathways permits progressive cell division until M2 (crisis) which 
is characterized by increasing cell death. The cells that continue through M2 generally 
become immortal (14-16). In contrast to most normal human somatic cells in which the 
telomerase activity is absent, most cancer cells (85-90%) have upregulated telomerase 
activity (17, 18); however, about 10-15% of tumors maintain telomere length by a 
mechanism called alternate lengthening of telomeres (ALT) (15). By permitting 
unlimited cell growth, immortalization increases the susceptibility of cells to 
tumorigenesis by providing more replicative capacity of cells so that cells can survive 
long enough to acquire multiple genetic alterations required for cancer.  
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Senescence was found to be the dominant trait over cellular immortalization. 
Somatic cell hybrids obtained from the fusion of normal human diploid fibroblasts with 
different immortal human cells exhibited limited cell proliferative potential, and that 
recessive changes of senescence genes, therefore, lead to immortalization (19-21). 
Moreover, a somatic cell hybridization study was performed to determine the 
complementation groups of cellular senescence and to narrow down the number of genes 
involved in this process (22). The series of cell fusion studies of different types of 
immortal cells regardless of cell types and tumor origins revealed four complementation 
groups: A, B, C, and D (22). The concepts behind this experiment were that if the 
immortal cell lines contain the same recessive changes, the hybrids of these two cell lines 
should be immortal and the cell lines would be assigned to the same complementation 
group. However, if the two cells had lost a different genetic function, the cell hybrid 
should have limited cell divisions and would be assigned to a different complementation 
group (23). Microcell-mediated chromosome transfers were later performed to identify 
chromosomes and genes altered in each complementation group. The results showed that 
chromosomes 1, 4, and 7 encode senescence genes inactivated in the complementation 
group C, B, and D, respectively (23, 24). Hensler et al (1994) showed that chromosome 
1q carries genes altered in cell lines assigned in complementation group C, which is 
involved in cellular senescence. Moreover, the deletion of two regions located on 
chromosome 1q (1q25 and 1q41-42) appeared to be involved in escaping senescence 
(25). The presence of four complementation groups involved in cellular senescence 
indicates that there are a limited number of genes and pathways controlling this process.  
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 The p53/p21Cip1 and p16INK4a/pRb tumor suppressor pathways are the principal 
regulators of cellular senescence (26). In human fibroblasts, binding and inactivating of 
p53 and pRb by DNA tumor virus oncoproteins, for example simian virus 40 (SV40) 
large T antigen, can cause a bypass of senescence (26). The ability of the DNA tumor 
virus such as SV40, Adenovirus 16 and 18, and the human papillomavirus (HPV) to 
transform human fibroblasts was demonstrated over 30 years ago to target p53 and pRb 
by inactivating these important tumor suppressor proteins. The tumor suppressor p53 
protein is bound and inactivated by the adenovirus E1B and simian virus 40 (SV40) large 
T antigen (27), and the human papillomavirus (HPV) E6 protein (28). Similarly, the E7 
oncoprotein of HPV (29, 30), SV40 large T antigen(31), and the adenovirus E1A protein 
(32) have been shown to interact with and inactivate pRb protein. p53 is a transcriptional 
activator and repressor that regulates the expression of cell cycle arrested genes or 
apoptosis in response to DNA damage. The DNA binding and transcriptional activities of 
p53 are increased in high passage normal cells (33). pRb regulates the expression of cell 
cycle regulated genes indirectly by inactivating the E2F transcription factor and 
recruiting chromatin-remodeling proteins to genes that control cell cycle progression and 
differentiation (34). Recently, several genes and pathways were revealed to regulate the 
induction of senescence or being responsible for bypassing senescence. For instance, 
gene involved in interferon pathway, IFI 16, (35), PAI-1 (a critical downstream target of 
p53) (36), pRb (37), PML (a component of nuclear bodies) (38), prohibitin (39), HBP1 
(40), p33ING (41), Bmi-1 (42), SUMO-2/3 (43), ING1a (44), IGFBP-rP1 (45), IRF5 and 
IRF7 (46), PPARγ (47) were shown to play a role in cellular senescence mechanism in 
mammalian cells. 
7 
 
 
1.3 Epigenetic regulation of genes and senescence 
Epigenetic mechanisms regulate the expression of genes including many tumor 
suppressor genes without changing DNA sequences. The silencing of tumor suppressor 
genes can lead to abnormal cell growth, failure of cell cycle arrest checkpoints and 
prevention of programmed cell death, all of which drive the development of tumors. 
There are two well accepted epigenetic mechanisms involved in the regulation of gene 
expression. Changes in DNA methylation at cytosine bases of promoter-containing CpG 
islands, and histone acetylation both can affect the compactness of chromosomes (15). 
Methylation of DNA, covalent addition of methyl group, occurs at the cytosine base at 
CpG dinucleotides, which in clusters are called the CpG islands. CpG islands are usually 
located at the promoter region (200-2000 bp) around the transcription start site (48). This 
region is normally unmethylated in transcriptionally active genes; however, abnormal 
methylation frequently occurs in human cancers (49). Tumor suppressor genes involved 
in several pathways such as cell cycle, DNA repair, and apoptosis are hypermethylated 
and silenced, for example, pRb, p16INK4a, p15INK4b, and BRCA1 (50). In mammalian 
cells, DNA methylation is catalyzed by DNA methyltransferase (DNMT) (51). The 
inhibition of DNA methyltransferase can, therefore, restore gene expression silenced by 
DNA methylation. 5-azacytidine and 5-aza-deoxycytidine (5-aza-dC) are DNMT 
inhibitors widely used to demethylate DNA and restore gene expression (52). 5-
azacytidine can be incorporated into DNA and RNA whereas 5-aza-dC can only be 
incorporated into DNA (53). Their structures are analogous to cytidine base; therefore, 
can be incorporated into DNA. DNMT is then irreversibly bound to 5-aza-dC residues in 
DNA resulting loss of activity (53). The treatment of immortal Li-Fraumeni Syndrome 
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(LFS) fibroblasts with 5-aza-dC can induce a senescence-like stage (54, 55). On the other 
hand, normal fibroblasts are not induced to senesce by treatment of 5-aza-dC because the 
promoters of tumor suppressor genes in normal cells are rarely silenced by promoter 
methylation. Certain genes were consistently found to be downregulated in immortal LFS 
fibroblasts and reactivated after 5-aza-dC treatment (55). This shows that genes involved 
in the immortalization and senescence processes can be regulated by DNA methylation 
(56). 
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1.4 Project background: Identification of genes associated with cellular 
immortalization and senescence in Li-Fraumeni Syndrome fibroblasts by 
microarray analysis 
1.4.1   Li-Fraumeni Syndrome and established immortal LFS cell lines 
The Li-Fraumeni Syndrome (LFS), described by Li and Fraumeni in 1969, is a 
rare familial inheritated cancer syndrome characterized by multiple primary tumors 
including breast carcinoma, soft tissue sarcoma, brain tumors, osteosarcoma, leukemia, 
lymphoma and adrenocortical carcinoma as well as early age of tumor onset (57). About 
75% of LFS patients exhibit heterozygous germ line mutations of the tumor suppressor 
gene p53 (57).  
Upon establishment in cell culture, dermal fibroblasts from seven LFS patients 
developed changes in morphology, anchorage-independent growth, and chromosomal 
abnormalities (58). These cells continued to proliferate and escaped senescence, and four 
of these (MDAH041, MDAH087, MDAH172, and MDAH174) spontaneously became 
immortal. Bischoff et al. established immortal LFS cell lines from these four individuals 
by skin biopsy and growth in culture (58). These immortal cells have several properties 
of transformed cells including an altered morphology and chromosomal anomalies. After 
becoming immortal, these cells can be transformed by an activated H-ras oncogene to 
form tumors in nude mice (59). In contrast, fibroblasts from normal donors almost never 
spontaneously immortalize. 
The MDAH041 cell line was developed from a female patient, and the established 
immortal cells have lost their wild-type p53 allele and contain only a p53 allele with a 
10 
 
 
point deletion mutation at amino acid 184 which results in a truncated p53 protein (60). 
This cell line, after becoming immortal, contains active telomerase and the telomere 
length is stabilized at ~4 kb (population doubling [PD] 84) (60). The MDAH087 cell line 
was established from a 24-year-old male LFS patient containing one wild-type p53 and 
one p53 allele with a missense RÆW point mutation at amino acid 248. Immortal 
MDAH087 cells have no detectable telomerase activity; however, the telomere length of 
this cell line, which is long (> 30 kb), is maintained by an alternative lengthening 
mechanism (ALT) (58, 60). The genomic analysis in these two cell lines showed that the 
remaining wild type p53 allele was lost in both cell lines. Subsequently, the three 
additional immortal LFS cell lines, MDAH087-1, MDAH087-10, and MDAH087-N, 
were independently developed from early passage precrisis MDAH087. 
Four immortal LFS fibroblasts, MDAH041, MDAH087-N, MDAH087-1, 
MDAH087-10, were used to characterize genes, pathways, and also mechanisms 
involved in cellular senescence and immortalization. The advantage of studying these 
cells is that they are spontaneously immortal compared with other cell lines induced to 
immortalize by chemicals or oncogenes. Two additional LFS fibroblast cell lines from 
sisters, MDAH172 and MDAH174, were also independently established, and they 
became immortalized spontaneously (Bischoff et al., 1990). These immortal cells contain 
only a mutant p53 with an R175H mutation. 
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1.4.2  Identification of genes and pathways altered during immortalization and 
senescence in LFS fibroblasts 
To identify gene and pathway changes during cellular immortalization and bypass 
of senescence, Fridman et al. used four immortal LFS cell lines and their precrisis 
counterparts to characterize gene expression by Affymetrix DNA microarray profiling 
analysis (55, 56). Gene expression of these spontaneously immortalized LFS cell lines 
was examined during immortalization by comparing gene expression changes of 
immortal LFS cell lines with their precrisis cells and gene expression changes of 
immortal LFS fibroblasts with senescence induced by treatment with 5-aza-deoxycytidine 
(5-aza-dC), an inhibitor of DNA methyltransferase. Since the senescence phenotype is 
dominant over immortalization, it was hypothesized that genes that are epigenetically 
silenced (downregulated) are the key regulators of cellular senescence. We identified 
genes downregulated during immortalization and upregulated after 5-aza-dC treatment as 
candidate senescence genes. In the microarray analysis, the immortal MDAH041 cell line 
was compared with the precrisis MDAH041 (MDAH041-PC) and the three immortal 
MDAH087 cells (MDAH087-1, MDAH087-10, and MDAH087-N) were compared with 
the precrisis MDAH087-PC cell line. Also, all four immortal cells treated with 5-aza-dC 
were compared with untreated immortal cells. In all four immortal LFS cell lines, the 
results showed that there were numerous genes downregulated during immortalization 
and upregulated after 5-aza-dC treatment. Among those genes, 187 genes downregulated 
during immortalization and 185 genes upregulated after 5-aza-dC treatment were 
commonly found in all four cell lines. Furthermore, 14 genes whose expression was 
decreased during immortalization and increased after 5-aza-dC treatment were common 
12 
 
 
among all four immortal cell lines. A schematic of microarray analysis is shown in Figure 
2. Gene ontology analysis was then performed to analyze the biological, cellular, and 
molecular characteristics of the genes differentially expressed during immortalization and 
after 5-aza-dC treatment. Three pathways were identified: cell cycle, cytoskeleton, and 
interferon pathways. There are several genes regulating the cell cycle that are involved in 
cellular senescence. The well-known cell cycle-regulated genes, p53/p21Cip1 and 
p16INK4a/pRb, have been shown to be increased in senescent cells and play an important 
role in immortalization and senescence (61-63). Among the fourteen genes epigenetically 
down-regulated during immortalization (56), four genes (CREG1, SERPINB2, 
IGFBPrP1, and ALDH1A3) were shown to regulate cell cycle. IGFBPrP1 or IGFBP3 
overexpression suppresses cell growth and inhibits colony formation in the immortal LFS 
cell lines (64). 
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Figure 2. A schematic of microarray analysis from LFS fibroblasts (Adapted from 
Fridman et al., 2006). Gene expression profiles were identified by Affymetrix microarray 
analysis comparing immortal LFS with precrisis cells and 5-aza-dC-treated immortal with 
untreated cells. CREG1 was identified in the group of genes that were downregulated 
during immortalization and reactivated in 5-aza-dc-induced senescence. 
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1.5 CREG1  
CREG1, the cellular repressor of E1A-stimulated genes 1, is a secreted 
glycoprotein containing 220 amino acids with three consensus N-glycosylation sites. The 
CREG1 gene is located at the 1q24 region of the chromosome. Human CREG1 DNA is 
98%, 80%, and 47% identical to chimpanzee, mouse, and Drosophila, respectively. The 
alignment of CREG1 protein among species is shown in Figure 3. The first 31 amino 
acids of human CREG1 are predicted to be a cleavable signal sequence (65). The crystal 
structure of CREG1 shows that it forms a tight homodimeric complex (66). CREG1 was 
first identified by yeast two-hybrid screen for proteins that interacted with the Drosophila 
TATA-binding protein, TBP. In addition, CREG1 shares sequence similarity with a 
region of the adenovirus E1A protein (Figure 4) (67). Adenovirus E1A protein contains 
the Rb binding motif and shares the capacity to form a complex with pRb to disrupt the 
interaction between pRb and E2F transcription factors (68). This favors the 
transcriptional activity of E2F target genes and cell cycle progression. The human 
CREG1 was shown to bind to TBP and Rb-family pocket proteins, pRb/p105, RbL1/p107 
and RbL2/p130 in vitro (67). 
CREG1 functions as transcriptional repressor by repressing E2F transcription 
activation and antagonizing the ability of E1A and ras to transform primary cells (66, 67). 
It enhances differentiation of embryonal carcinoma cells and its expression increases in 
differentiated cells (65). Overexpression of CREG1 in human teratocarcinoma cells 
decreases cell cycle progression and cell proliferation (69). The secreted form of CREG1 
interacts with its putative receptor, insulin-like growth factor 2 receptor (IGF2R), for 
endogenous localization and its growth suppression activity is IGF2R-dependent (69, 70). 
15 
 
 
Moreover, Han et al. demonstrated a role for CREG1 in vascular cells showing that 
CREG1 promotes differentiation and growth arrest in this cell type (71). Adenovirus-
mediated CREG1 transfer to balloon-injured arteries reduces vascular hyperplasia (72), 
CREG1 overexpression was shown to attenuate cardiac hypertrophy in mice, involving 
downregulation of ERK signaling (73), inhibiting vascular smooth muscle cell migration 
as well as reducing activity and expression of MMP-9 protein with increased protein 
expressions of TIMP-1 and TIMP-2 (74).  
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Figure 3. The amino acid sequences alignment of CREG1 among species. The box 
shows position of homology to the amino acid sequence with E1A oncoprotein Rb 
binding site. The black line indicates the cleavage signal sequence in human homologue. 
The amino acid sequences of CREG1 were obtained from NCBI database (human 
NP_003842, chimpanzee XP_001157266, Mouse NP_035934.1, Chicken LOC768680, 
Drosophila NP_524385). Protein alignment was performed using ClusterW2 tool 
(http://www.ebi.ac.uk/Tools/clustalw2/index.html) 
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1.6 p16INK4a/pRb pathway and its regulation of cellular senescence 
The p16INK4a tumor suppressor protein plays a very important role on cell cycle 
regulation. It binds to and inhibits the kinase activity of the CDK4-6/cyclin D complex 
preventing the phosphorylation of Rb-family members (75). Thus, p16INK4a maintains Rb 
family proteins in a hypophosphorylated state to promote the inactivation of E2F 
transcription factor, preventing entry into the cell cycle. The p16INK4a gene (CDKN2A) is 
located at the INK4a/ARF/INK4b locus on chromosome 9p21 which encodes three 
related genes and distinct tumor suppressor proteins (ARF, p15INK4b, and p16INK4a) (76). 
Genetic alterations (gene deletion, intragenic mutation and methylation-mediated 
silencing) of p16INK4a and its related INK4 family members, are among the most frequent 
found in human cancer (75). The expression of p16INK4a can also be repressed by several 
factors including the polycomb complexes (77), the helix-loop-helix Id1 protein (78). 
The retinoblastoma protein or pRb and its homologues RbL1/p107 and 
RbL2/p130, bind and inhibit several transcription factors including the E2F family of 
transcription factors. Different Rb family members regulate different sets of E2Fs. pRb 
preferentially binds to activator E2Fs, E2F1-3, whereas p107 and p130 bind the repressor 
E2Fs, E2F4 and E2F5 (79). Progression through cell cycle requires phosphorylation of 
Rb family members by the CDK4-6/cyclin D complex to favor the transcriptional activity 
of E2F transcription factors. Accordingly, the function of p16INK4a is essential for a 
functional Rb checkpoint and overexpression of p16INK4a in cells with a wild type pRb 
can result in cell cycle arrest or senescence (80, 81). 
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1.7 Purpose of the study 
The loss of senescence response appears to be an important step in the 
development of cancer. To gain more knowledge on cellular senescence, and further 
understand mechanisms that regulate this process, the Tainsky lab had previously 
identified genes and pathways altered to bypass senescence (56). To investigate the role 
of a candidate senescence-associated gene, I present here the functional study of CREG1 
gene and its implication in cellular senescence using immortal LFS fibroblasts and cancer 
cells as a model. Its function related to cell cycle regulation, negative growth effects, and 
the transcriptional repression of E2F, indicated that this gene may be a pleiotropic 
regulator of cellular senescence. 
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CHAPTER 2  
METHODS 
2.1  Cell lines and cell culture conditions 
Six independent immortal LFS cell lines were derived from primary fibroblasts by 
skin biopsy from four independent LFS patients, MDAH041, MDAH087, MDAH172 
and MDAH174, and were spontaneously immortalized in vitro (58). Immortalized LFS 
fibroblasts, normal fibroblast CRL-1502, HT1080 fibrosarcoma, and SaOS2 
osteosarcoma cell lines were grown in Modified Eagles Medium (MEM, Invitrogen), and 
the U2OS osteosarcome cell line was cultured in RPMI medium 1640 (Invitrogen). All 
cell lines were supplemented with 10% fetal bovine serum (FBS, Hyclone), 100 units/ml 
penicillin and 100 µg/ml streptomycin (Invitrogen) and were maintained at 37oC in 5% 
humidified CO2. 
2.2 Plasmids and DNA transfection 
A CREG/pRC plasmid was kindly provided by Dr. Grace Gill from Tufts 
University. A 675-bp cDNA fragment of CREG1 was amplified from the CREG/pRC 
plasmid with primers flanking EcoRI and BamHI restriction sites (forward primer 5’-
GATATCGAATTCCATATGGCCG and reverse primer 5’- 
GGGATCCTCTAGACCACAGTCT) and was cloned into a pIRESpuro vector. 
CREG/pcDNA3.1-Hygromycin was generated by ligation of a CREG fragment digested 
from CREG/pRC into HindIII and XbaI sites of pcDNA3.1-Hygro. p16INK4a was cloned 
into a pcDNA3.1HisB vector.  
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In the functional study of CREG1, immortal LFS cell lines MDAH041 and 
MDAH087-1, as well as U2OS, SaOS2, and HT1080 cancer cell lines (6-9 x 105 cells in 
10-cm culture plate) were transfected with 2 µg of CREG1-pIRESpuro and pIRESpuro 
empty vectors using lipofectamine transfection reagent and plus reagent (Invitrogen). For 
stable transfection, transfected cells were selected in standard culture media containing 
0.5 µg/ml puromycin (Sigma-Aldrich) at 48 h after transfection. Stably transfected cells 
were used for cell growth assays including cell count, MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) colorimetric and colony formation assays after 1 
week of selection. Expression of genes was confirmed by Western blot analysis 
In the coexpression of CREG1 and p16INK4a experiment, cells were transfected 
with four expression conditions, 1) empty vector pIRES and pcDNA3.1, 2) CREG1-
pIRES, 3) p16-pcDNA3.1, 4) CREG1-pIRES and p16-pcDNA3.1. Two µg of each vector 
were cotransfected using lipofectamine transfection reagent and plus reagent (Invitrogen). 
At 48 h posttransfection, the cells were selected in combination of 0.5 µg/ml puromycin 
(Sigma-Aldrich) and 200 µg/ml G418 (Gibco) (double drug selection). Control 
untransfected cells died at day 3 after selection. At 5 days after selection, stable 
transfected cells were harvested for western blotting, flow cytrometry for cell cycle 
analysis, seeded for colony formation assay, or fixed and senescence-associated β-
galactosidase stained to detect senescence. 
2.3 5-aza-dC treatment and gene expression analysis by Q-RT-PCR 
5-aza-deoxycytidine (5-aza-dC) (Sigma-Aldrich) treatment of immortal LFS 
fibroblasts was performed as described by Fridman et al.(56). Briefly, immortal LFS 
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fibroblasts (3x105 cells) were treated with 1 µM 5-aza-dC in H2O every other day for 1 
week (media containing 5-aza-dC was changed on day 2, 4, 6) and cells were harvested 
for protein and RNA at day 8 of the experiment. Total RNA was isolated from immortal 
and 5-aza-dC-treated immortal LFS cell lines using the QIAGEN RNeasy Kit 
(QIAGEN). cDNA was prepared from 2 µg of RNA using Superscript II (Invitrogen). Q-
RT-PCR was performed using SYBR Green PCR Detection Kit (PE Biosystems) and 
analyzed on the ABI 5700 Sequence Detection System (Applied Biosystems). Primers for 
CREG1 Q-RT-PCR were Forward-5’ CAGCTTCAGCCAGGGACAAA and Reverse-
5’GGGCAGTTGAGGAAGCCTTAG, and GAPDH was used as an internal control. 
Primers for cyclin A2 Q-RT-PCR were forward-5’ AGTGATGTTGGGCAACTCTG and 
reverse-5’TCCGGGTTGATATTCTCCTG. The relative fold change was calculated 
using CT method as follows: 2-ΔΔCT, where, ΔΔCT = (CT Gene of interest - CT GAPDH) experiment - 
(CT Gene of interest - CT GAPDH) control (82). The calculated relative fold change between 0 and 1 
was divided by -1. 
2.4 Methylation analysis of CREG1 promoter  
CpG islands in the promoter of CREG1 were identified using MethPrimer 
software (http://mail.ucsf.edu/urolab/methprimer/index1.html). The region of gene, -1000 
to +500 regarding the transcription start site, was identified using UCSC Golden Path 
(http://genome.ucsc.edu). Genomic DNA prepared by Puregen DNA isolation kit (Gentra 
System) was modified with bisulfite as described by Li Q et al (2008). Briefly, 1 µg of 
genomic DNA was denatured and treated with 3.6 mol/L sodium bisulfite. The modified 
DNA was resuspended in water and amplified by PCR with two nested PCR reactions. 
The two sets of primers were, F1 5’-TTAAAAGGAGGGGGTGTGTG (-274), and R1 
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5’-CGAACCCCAACTCACCTACA (+1297); F2 5’-TGCGGAGTTGTAGAGGGATT (-
65) and R2 5’-CCGCCTCCAACGTAAAAATA (+316). The numbers in parentheses 
indicate the position relative to the transcriptional start site of CREG1 (NM_003851). 
The PCR products were cloned into pCR2.1-TOPO vector (Invitrogen) using the TOPO-
TA cloning kit (Invitrogen). Sequencing of ten colonies was performed using M13-
reverse and T7 primers. The sequencing results were analyzed by MethTools software 
(http://genome.imb-jena.de/methtools/). 
2.5 Western blotting 
To isolate protein, cells were washed with cold PBS and cold lysis buffer (50 mM 
Tris-HCl pH7.4, 150 mM NaCl, 1% NP40, 0.25% Na-deoxycholate, 1 mM EDTA), 1 ml 
lysis buffer containing 10 µl of the following; protease cocktail inhibitor, PMSF (10 
mg/ml in isopropanol), Sodium pyrophosphate (0.1M), Sodium fluoride (1M) and 
Sodium orthovanadate (1M), was added and the cell lysates were collected by scraping 
cells from plates and centrifugating at 14000 rpm for 15 minutes. Equal amounts of 
protein (40-60 µg) were loaded onto 10 or 12% polyacrylamide gels, electrophoresed, 
and transferred onto nitrocellulose membrane. The membrane was blocked in 5% dry 
milk in Tris-buffered saline tween-20 (TBST). Proteins were detected by incubating 
overnight with primary antibodies diluted in 5% dry milk in TBST following by 1 h 
incubation with secondary antibodies. The primary antibodies used (mostly 1:1000 
dilution) are shown in Table 1. The Alexa Fluor 680-labeled secondary antibodies were 
from Molecular Probes or the Li-Cor IRDye 800-labeled secondary antibodies were from 
Rockland Immunochemical. The working dilution for secondary antibodies was 1:10,000. 
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The images were detected using the Odyssey Infrared Imaging System (Li-Cor 
Biosciences). 
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Table 1. The primary antibodies used 
Antibody Dilution Catalog number Supplier Host 
CREG1 1:1000 AF2380 R&D system Goat 
p16INK4a 1:1000 554079 BD Biosciences Mouse 
p21WAF1 1:1000 05-345 Upstate Mouse 
Cyclin A2 1:1000 611268 BD Biosciences Mouse 
Cyclin B1 1:1000 Ab72 Abcam Mouse 
Cyclin D1 1:1000 2926 Cell Signaling Mouse 
IGF2R 1:1000 Sc-25462 Santa Cruz Rabbit 
pRb 1:1000 9309 Cell Signaling Mouse 
p107/Rbl1 1:1000 Sc-318 Santa Cruz Rabbit 
p130/Rbl2 1:1000 Sc-317 Santa Cruz Rabbit 
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2.6 Senescence-associated β-galactosidase assay 
Senescent cells express high β-galctosidase activity which can be detected 
through 5-bromo-4-chloro-3-indolyl β-D-galactopyranoside (X-gal) hydrolysis at pH 6 
(10). A senescence detection kit (BioVision) was used for staining according to the 
manufacturer’s instructions. Briefly, stably tranfected cells were stained for senescence-
associated β-galactosidase activity after 5-7 days of drug selection. In order to count the 
senescence-associated β-galactosidase positive cells, stably transfected cells were seeded 
at equal amount (1x105 cells in 60-mm culture plate) after stable transfection and stained 
24 h later. Cells were washed twice with PBS and fixed with fixative solution for 10-15 
minutes. The fixed cells were stained with the staining solution containing X-gal and 
incubated at 37oC overnight.  
2.7 Colony formation assay 
To determine the ability of stably transfected cells to form colonies, cells stably 
transfected with CREG1 and p16, alone and in combination, were seeded at low density 
(1000-5000 cells depending on cell lines) on 10-cm culture plates in triplicate and 
cultured under drug selection, as described in section 2.2, for 2 weeks. The colonies were 
washed twice with PBS, fixed with 4 ml cold methanol for 10 minutes, air dried, stained 
with 5 ml diluted Giemsa (1:10 v/v in H2O) (Sigma-Aldrich), and incubated at room 
temperature for 30 minutes. The plates were then rinsed with water and air dried. The 
colonies (>1mm diameter) were counted and mean percentages were calculated from at 
least two independent experiments. 
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2.8 MTT cell proliferation assay 
 The MTT tetrazolium salt (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium) 
colorimetric assay was used to quantify metabolically active cells. After stable 
transfection, cells were seeded at a density of 2000 cells per well in a 12-well plate and 
the MTT assay was measured every 3 days for two weeks. Stock 2 mg/ml filtered MTT 
(Sigma-Aldrich) solution was diluted 1:10 in culture media. One ml diluted MTT was 
added to each well and the plates were incubated 1.5 h at 37 oC, 5% CO2. MTT was 
aspirated and 1 ml DMSO was added to each well. The plates were shaken at room 
temperature for 10 minutes. 100 µl of cell extract was pipetted into a 96 well plate and 
the absorbance was measured at 540 nm on a Dynatech-MR-500 plate reader (Dynatech 
Laboratories). Absorbance is directly proportional to the number of live cells. 
2.9 Flow cytrometry analysis 
Stably transfected cells were trypsinized, counted, and 106 cells were washed in 5 
ml phosphate buffered saline (PBS) and centrifuged at 200 x g. The resuspended cells 
(0.3 ml PBS) were fixed by adding 1 ml of cold 95% ethanol with mixing and incubated 
at -20 oC overnight. The fixed cells were centrifuged at 200 x g and the ethanol was 
removed by pipetting. The cell pellets were stained with 1 ml of propidium iodide (PI) 
staining solution containing 50 µg/ml PI (Invitrogen), 200 µg/ml RNaseA and 0.1% 
Triton X-100 in PBS and incubated at room temperature for 30 minutes. The DNA 
content was measured at the Karmanos Cancer Institute Flow Cytometry Core using the 
Becton-Dickinson FACSCalibur TM Cytometer. 
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2.10  Reporter gene assay 
The cyclin A2 wild-type promoter reporter was generated by cloning of a 347-bp 
fragment (-75 to +272) of the cyclin A2 promoter into the KpnI and HindIII restriction 
sites of the pGL3-basic vector containing luciferase reporter gene (83). The following 
primers were used to PCR amplify the promoter fragment from genomic DNA of normal 
fibroblast CRL-1502, forward 5’-GCAGGGTACCTGTCGCCTTGAATGACGTCA-
3’and reverse 5’-GCAGAAGCTTCACTGCTCCCGGGAGTGGAC-3’. To generate the 
cyclin A2Δ with deletion of the CRE element of the cyclin A2 promoter, the following 
primers were used, 5’-GCAGGGTACCGGCCGCGAGCGCTTTCATTG-3’ and reverse 
5’-GCAGGGTACCGGCCGCGAGCGCTTTCATTG-3’. The E2F reporter was 
constructed by cloning the fragment of oligonucleotide containing four consensus E2F 
binding sites with TATA promoter sequence into KpnI and HindIII sites of pGL3-basic 
vector. The E2F1 promoter reporter containing E2F1 promoter-driven luciferase gene 
was kindly provided by Dr. Gustavo Leone from Ohio State University. The E2F1/CMV 
expression plasmid was kindly provided by Dr. Joseph R. Nevins from Duke University. 
U2OS cells (40,000) were transfected with 2 µg of each expression vector in a six-well 
cultured plate in triplicate. Selective media was added at 48 hours after transfection. Two 
µg of the cyclin A2 reporter construct and 0.01 µg of TK-renilla expression vector for 
normalizing the transfection efficiencies were transfected at day 3 after selection. In the 
E2F-TA reporter experiment, 1 µg of E2F-TA reporter, 0.5 µg of E2F1/CMV expression 
vector and 0.01 µg TK-renilla were transfected after expression vector transfection as 
described above.  The cells were then harvested for luciferase assay at 40 h after the 
transfection of reporter plasmids. The luciferase activity was tested with the dual-
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luciferase reporter assay system (Promega) according to the manufacturer’s instructions. 
The luciferase activity was calculated from three independent experiments. 
2.11 Lifespan analysis 
To analyze the lifespan of CREG1-transfected immortal LFS cells, MDAH087-1 
was transfected with CREG1 or pIRES followed by drug selection for two weeks. Ten 
individual clones from CREG1 and pIRES transfected cells were selected and transferred 
to 24-well plate using cloning cylinders. The cells were then transferred to 10-cm plates 
and cultured to obtain a confluent plate for analysis. 1x105 cells were seeded at day 1 and 
the cell number was counted at day 7. The population doublings were calculated from the 
total cell number by applying log2. The cells were re-plated at 1x105 and continued 
counting until the PD exceeded 50. 
2.12 Coimmunoprecipitation  
Coimmunoprecipitation was performed to detect CREG1-interacting proteins. 
MDAH087-1 immortal cell clones stably transfected with CREG1 and pIRES vectors as 
well as U2OS cell line transiently transfected with CREG1 and p16 were used in this 
assay. The EZview Red Protein A and G Affinity gel beads (Sigma-Aldrich) were used 
according to the manufacturer’s instruction. To prepare cell lysate, cells (70-80% 
confluency in 10-cm culture plate) were washed with ice cold PBS and lysed by scraping 
in RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP40, 0.25 % Na-
deoxycholate, 1 mM EDTA) containing 10 µl protease inhibitor cocktail and 10 µl PMSF 
(10 mg/ml). Cell lysates were centrifuged for 15 minutes at 10,000 rpm at 4oC and 
supernatant was retained. Cell lysates were pre-cleared by adding 50 ul of RIPA buffer-
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washed beads followed by incubating at 4oC for 10 minutes with thorough mixing. The 
beads were removed by centrifugating at 14,000 rpm at 4oC for 10 minutes and the 
supernatant (cell lysate) was retained. For immunoprecipitation, one µl of antibody was 
added to cell lysate (500-1000 µg protein) and the total volumes of the reactions were 
adjusted to equal volumes by cold lysis buffer. The antibody-cell lysate mixtures were 
incubated with thorough mixing at 4oC overnight. In the washing step, 50 µl of the 
protein A or G agarose beads slurry (50%) was transferred into a microcentrifuge tube 
and washed twice with cold lysis buffer. The beads were resuspended in 50 µl of cold 
lysis buffer and transferred into the antibody-lysate mixture followed by incubation for 1 
hour at 4oC. The mixture was then centrifuged for 30 seconds at 10,000 rpm and the 
supernatant was carefully aspirated. The beads were washed by pipetting with cold lysis 
buffer three times. To elute the antibody-antigen complexes for SDS-PAGE, 25 µl of 
lysis buffer and 25 µl of 2x loading buffer were added to the beads. The samples were 
then boiled for 5 minutes to dissociate the immunocomplex from the beads. Ten to 
twenty µl of the supernatant was subjected to denaturing gel electrophoresis.  
2.13     Preparation of nuclear extracts 
 To detect whether CREG1 is mainly found in the nucleus or cytoplasm, nuclear 
extracts from MDAH087-1 cell clones stably expressing pIRES empty vector and 
CREG1 were prepared to characterize CREG1 localization. The protocol was adapted 
from previously published methods (84). Briefly, 10-cm culture plates (107 cells) were 
placed on ice for 10 minutes. Cells were then washed twice with cold PBS and washed 
once with 1.5 ml Buffer A (10 mM Hepes pH7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM 
DTT, 0.1% igepal, 1% protease cocktail inhibitor). One ml of Buffer A was added to 
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each plate followed by incubating on ice for 10 minutes with shaking. Cells were 
collected by scraping into a glass homogenizer and were homogenized with type B pestle 
for 10-15 strokes. The homogenized extracted from each plate were collected into a 
single 15 ml tube and were centrifuged at 7000 rpm, 4oC, for 10 minutes. The supernatant 
(cytosolic fraction) were saved. The nuclear pellet was resuspended in 40 µl Buffer C (20 
mM Hepes pH7, 25% glycerol, 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 1% 
protease cocktail inhibitor, 0.5 mM PMSF, 1mM DTT) by pipetting and incubated at 4oC 
for 2 h with shaking. The mixtures were centrifuged at 14,000 rpm at 4oC for 5 minutes 
and the supernatant (nuclear extract) were collected.  
2.14    Knockdown of Rb family members and transfection 
U2OS cells expressing three members of the Rb family were used in this 
experiment. Each of the Rb pocket proteins, pRb, p107 and p130 was knocked down 
using the trans-lentiviral GIPZ packaging system (OpenBiosystems). To produce the 
lentiviral particles targeting each Rb pocket protein and non-silencing control, 9 ug of the 
pGIPz-shRNAmir constructs for each Rb member (pRb# RHS4430-98853387, 
p107#RHS4430-98851876, p130#RHS4430-99160980) as well as a non-silencing control 
vector obtained from Karmanos Cancer Institute shRNA shared resource together with 
the trans-lentiviral packaging plasmid mix (OpenBiosystems) were transfected into TLA-
HEK293T cells using Arrest-In transfection reagent (OpenBiosystems) according to the 
manufacturer’s instruction. The supernatant containing the virus was harvested and 
combined at 48 h and 72 h post-transfection. The virus stock was concentrated by 
ultracentrifugation using SW28 ultracentrifuge tube and the virus particles were 
resuspended into 100-200 µl media. U2OS cells were infected by the virus followed by 
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drug selection (0.5 µg/ml puromycin) beginning at 48h after infection. The cells 
expressing GFP proteins were examined by microscope to confirm the infection 
efficiency. One week after infection, the colonies were pooled (>20 colonies) and used 
for further experiments.  
To study the role of each Rb family member in the enhancement of CREG1 on 
p16-induced cellular senescence, U2OS stably infected with lentivirus targeting each of 
the Rb pocket proteins, non-silencing control (passage 4-8) and uninfected cells were 
used in coexpression of CREG1 (CREG/pcDNA3.1-hygro) and p16 (p16/pcDNA3.1-
Neo) experiments as mentioned above. Three selection drugs, puromycin (Sigma-
Aldrich) (0.5 µg/ml), hygromycin (Invitrogen) (200 µg/ml), and G418 (Gibco) (200 
µg/ml) were used to select transfected cells at 48h after transfection. 
2.15  Statistical analysis 
 The student’s two-tailed t-test for independent samples (unpaired t-test) was used 
to test the statistic significant of the effect of CREG1 and control pIRES overexpression 
on cell growth by colony formation assay. The same method was applied to test for 
differences in cell growth (colony formation assay), senescence-associated β-
galactosidase activity and reporter gene assay of p16 overexpression alone and in 
combination of CREG1 and p16. One way analysis of variance (ANOVA, Tukey’s test) 
was used to test for differences on coexpression of CREG1 and p16 experiment (vector, 
CREG1, p16, CREG1+p16 transfection conditions). A P-value ≤ 0.05 was considered to 
be statistically significant. 
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CHAPTER 3 
FUNCTIONAL ANALYSIS OF CREG1 
3.1 Summary 
CREG1 was identified from gene expression profiling by microarray analysis as a 
gene whose expression fits the criteria of a senescence-associated gene: downregulated 
during immortalization and reactivated by 5-aza-dC induced senescence. Moreover, 
CREG1 was attractive for this study because it is involved in control of E2F transcription 
activity. CREG1 downregulation was validated by quantitative real-time PCR and 
western blot analysis from six independent immortalized LFS cell lines. CREG1 
expression was reactivated after treatment of immortal LFS fibroblasts with 5-aza-dC, 
which can be used to induce senescence in immortal LFS cells. Promoter analysis of 
CREG1 revealed the presence of CpG islands and bisulfite sequencing of a selected 
region on the CpG island showed that hypermethylation of CREG1 promoter in immortal 
LFS cells compared with precrisis counterparts was related to the level of gene 
expression. Ectopic expression of CREG1 in immortal LFS cell lines and related cancer 
cell lines, osteosarcoma and fibrosarcoma cells, decreased cell proliferation but did not 
induce senescence. 
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3.2 CREG1 expression in immortal LFS fibroblasts 
3.2.1 Identification of CREG1 as a candidate senescence-associated gene by 
microarray analysis  
Fridman et al. previously identified the gene expression profiling changes during 
cellular immortalization in four independent, spontaneously immortalized LFS cell lines 
by Affymetrix microarray analysis to compare gene expression profiles of precrisis with 
immortal LFS fibroblasts as well as 5-aza-dC-treated immortal LFS with untreated cells 
(56). This study identified groups of genes and pathways including interferon, cell cycle 
and cytoskeleton altered in the process of immortalization. Genes that were 
downregulated during immortalization and upregulated after 5-aza-dC treatment to 
induce senescence are of the most interest for further study because cellular senescence is 
a tumor suppressive mechanism which can be bypassed by changes in tumor suppressor 
genes. In addition, the cell hybridization study revealed cellular senescence is dominant 
over immortalization, and that treatment of 5-aza-dC induces a senescent phenotype; 
therefore, genes epigenetically silenced are more critical in bypassing cellular senescence 
to become immortal. 
CREG1 is one of fourteen genes whose expression decreased during 
immortalization and increased in 5-aza-dC-induced senescence. The Affymetrix 
microarray data obtained by Fridman et al. (56) of CREG1 expression (fold change) from 
four independent immortal LFS cell lines is shown in Figure 4. CREG1 expression, 
downregulation during immortalization and upregulation after 5-aza-dC treatment which 
was demonstrated to induce senescence in immortal LFS cells (55), fit the criteria of 
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senescence associated genes and led to further investigation of the CREG1 role in cellular 
senescence. 
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Figure 4. Expression of CREG1 by Affymetrix microarray analysis. The dark bars show 
the fold changes (log2) of CREG1 expression in immortal LFS cell lines (IM) compared 
with precrisis cells (PC) and the light bars represent the fold changes in 5-aza-dC treated 
immortal cells (5aza) compared with untreated LFS cells (IM). The data was obtained 
from Fridman et al (56). CREG1 expression is downregulated in immortal cells and is 
upregulated after 5-aza-dC treatment. 
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3.2.2 Validation of CREG1 expression by quantitative real-time PCR 
To verify the microarray data of CREG1 expression, quantitative real-time PCR 
(Q-RT-PCR) was performed to measure CREG1 expression at mRNA levels in four 
immortal LFS cell lines used in microarray analysis, MDAH041, MDAH087-1, 
MDAH087-10 and MDAH087-N. Two additional immortal LFS cell lines, MDAH172 
and MDAH174, which were not included in gene expression profiling study provided an 
independent validation. Total RNA was isolated from precrisis (PD<30) and immortal 
(PD>150) LFS fibroblasts as well as 5-aza-dC-treated and untreated immortal cells for 
cDNA preparation and Q-RT-PCR. The Q-RT-PCR analysis of CREG1 was performed in 
triplicate from two independent RNA preparations. The average fold changes of gene 
expression by Q-RT-PCR are shown in Figure 5. The expression of CREG1 mRNA 
decreased in all immortal cell lines compared with their precrisis counterparts and 
increased after treatment with a DNA demethylating agent compared with untreated cells, 
which was consistent with the microarray data. 
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Figure 5. The expression of CREG1 by Q-RT-PCR. CREG1 expression was examined 
by Q-RT-PCR analysis in six independent immortalized LFS fibroblasts. The dark bars 
show fold changes of CREG1 in immortal LFS (IM) cells compared with precrisis (PC) 
fibroblasts derived from the same patient. The light bars represent the fold changes of 
immortal cells treated with 5-aza-dC compared to untreated immortal cells. GAPDH 
mRNA was detected from the same sample for normalization. The bar graphs represent 
the mean fold changes from two different sets of RNA preparation with three replicate for 
each reaction. CREG1 mRNA levels decrease in immortal LFS fibroblasts and reactivate 
after 5-aza-dC treatment. 
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3.2.3 Western blot analysis of CREG1 
To expand on the Q-RT-PCR results, CREG1 protein levels were measured by 
western blotting from precrisis and immortal LFS cell lines (Figure 6) and 5-aza-dC 
treated immortal cells (Figure 7). Additionally, the protein levels of CREG1 were 
measured from normal and LFS cells at replicative senescence. The population doublings 
of replicative senescent LFS fibroblasts are slightly varied among four independent cells 
lines; MDAH041 (PD43), MDAH087 (PD61), MDAH172 (PD51), MDAH174 (PD52) 
and normal fibroblast CRL-1502 (PD46). Interestingly, the protein levels of CREG1 were 
upregulated in replicative senescent LFS and normal CRL-1502 fibroblasts, as shown in 
Figure 6.  
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Figure 6. Western blot analysis of CREG1 in normal and LFS fibroblasts. CREG1 
protein levels were examined in normally growing and in replicative senescent fibroblast 
CRL1502 and LFS precrisis (PC), immortal (IM) and senescent (sen) fibroblasts. The 
population doublings (PD) of examined fibroblasts are indicated as followed; 1502 
(PD21), 1502 sen (PD46), 174 PC (PD13), 174 IM (PD132), 174 sen (PD52), 172 PC 
(PD14), 172 IM (PD172), 172 sen (PD51), 087 PC (PD26), 087-1 IM (PD298), 087-10 
IM (PD258), 087-N IM (PD250), 087 sen (PD61), 041 PC (PD 19), 041 IM (PD351), 041 
sen (PD 43). CREG1 protein levels are increased in replicative senescent fibroblasts 
compared with precrisis and immortal cells. The expression of CREG1 protein in 
MDAH087 senescent cells is somehow similar to precrisis cells.  
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Figure 7. Western blot analysis of CREG1 in 5-aza-dC treatment of immortal LFS cell 
lines. CREG1 proteins were detected in six independent immortal LFS cell lines 
untreated (UT) and treated (5aza) with 1µM 5-aza-dC. The bar graphs show CREG1 
level normalized to tubulin. CREG1 protein levels are upregulated after 5-aza-dC 
treatment in immortal LFS fibroblasts. 
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3.3 Analysis of CREG1 promoter and bisulfite sequencing 
Treatment with DNA demethylating agent 5-aza-dC can reactivate CREG1 
expression in immortal LFS cells. DNA methylation at promoters of genes has been 
shown to silence gene expression, including many tumor suppressor genes in cancer cells 
(49). To investigate whether CREG1 expression is regulated by promoter methylation, 
we analyzed the region of CREG1 promoter, -1000 to +800 bp relative to the 
transcription start site using MethPrimer software. We found that the promoter of CREG1 
contains CpG rich islands (Figure 8). Sodium bisulfite-modified genomic DNA samples 
from immortal and precrisis LFS fibroblasts were PCR amplified followed by sequencing 
at the CpG rich region. The region of CREG1 promoter analyzed (383 bp) is highly 
methylated in immortal MDAH041 cells (60%) and partially methylated in MDAH087-1 
(30%) and MDAH087-10 (10%) compared to their precrisis counterparts (Figure 9). The 
degree of promoter methylation seemed to correlate with the expression level of CREG1; 
lower CREG1 expression and higher methylation status was observed in MDAH041 than 
those in MDAH087, and this was also true for degree of promoter methylation and 
expression levels in MDAH087-1 compared with MDAH087-10. However, CREG1 
expression may not only be regulated by promoter methylation as we observed the partial 
methylation in MDAH087-1 and low methylation in MDAH087-10. In this case, other 
transcriptional mechanisms may also regulate CREG1 expression. 
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Figure 8. Schematic of CREG1 promoter from -1000 to + 800 bp relevant to the 
transcription start site (TSS). The blue area shows the CpG rich region and the red 
vertical bars represent the CpG sites. The black line represents the region analyzed by 
bisulfite sequencing. 
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Figure 9. Bisulfite sequencing of the CREG1 promoter from precrisis (PC) and immortal 
(IM) MDAH041, MDAH087-1 and MDAH087-10. The black circles represent the 
methylated CpG sites, whereas the white ones represent the unmethylated CpG sites. 
44 
 
 
3.4 CREG1 overexpression in immortal LFS and cancer cell lines 
3.4.1    Overexpression of CREG1 decrease cell proliferation in immortal LFS cells 
 The upregulation of CREG1 in replicative and 5-aza-dC-induced senescent 
fibroblasts and its silencing by promoter methylation led us to further investigate whether 
CREG1 was functionally involved in cellular senescence. We transfected CREG1 and a 
control empty vector into two immortal LFS cell lines, MDAH041 and MDAH087-1, and 
investigated consequent growth properties and senescence. CREG1 was cloned into the 
pIRESpuro expression vector. This vector is a bicistronic expression plasmid containing 
an internal ribosome entry site (IRES) which enables two genes of interest (CREG1 and 
puromycin resistant gene) to be expressed simultaneously. For stable transfection, two µg 
of CREG/pIRES or pIRES empty vectors were transfected into MDAH041 and 
MDAH087-1 immortal LFS cell lines. Forty eight hours posttransfection, transfected 
cells were selected with puromycin (0.5 µg/ml) and selective media was changed every 3 
days for 2 weeks. Drug selection maintained expression in the transfected cells 
containing gene of interest and control empty vector for further investigation of the 
effects of the transfected gene. Stably transfected cells were split for growth assay, 
including cell counting, MTT cell proliferation assay, colony formation assay and 
lifespan analysis. Transfected cells (2000 cells) were seeded into 24-well plate and 
cultured over two weeks for cell growth analysis by cell counting and MTT assay. Cell 
proliferation assay using both cell counting (Figure 10) and MTT assay (Figure 11) of 
stably transfected MDAH041 and MDAH087-1 immortal cells showed decreased cell 
growth of CREG1 transfected cells compared with pIRES transfected control cells. To 
further confirm the effect of CREG1 on cell proliferation, the stably transfected cells 
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were seeded at low density (1000-5000 cells in 10-cm culture plates) to measure the 
ability to form colonies under the condition of drug selection for two weeks followed by 
Giemsa staining. As shown in Figure 12, CREG1 overexpression in immortal LFS cells 
exhibited decreased colony number compared with pIRES transfected cells. 
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Figure 10. Cell growth assay of MDAH041 and MDAH087-1 transfected with CREG1 
and control pIRES vectors. After stable transfection, 1000 cells were seeded into 24-well 
plates in triplicate and cell number was counted every 2 days. The data point with the 
standard deviation shows the result from the representative experiment of at least two 
independent experiments. CREG1-overexpressing cells grow slower than control cells in 
two independent LFS immortal cell lines.  
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Figure 11. MTT cell proliferation assay of MDAH041 and MDAH087-1 immortal cells. 
After stable transfection, 2000 cells were seeded into 24-well plates in triplicate and the 
MTT assay was conducted every 2 days for 2 weeks. The data point with the standard 
deviation shows the result from the representative experiment of at least two independent 
experiments. Overexpression of CREG1 decreases cell proliferation in two independent 
immortal LFS cell lines.  
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3.4.2    Lifespan analysis of CREG1 overexpressing immortal LFS cells 
 To further investigate the negative growth effects of CREG1 and whether stable 
expression of CREG1 affect the lifespan of immortal cells, the lifespan (population 
doubling) of cells expressing vector control and CREG1 was examined. The population 
of stably transfected cells was homogenous and derived from a single clone. MDAH087-
1 immortal cells were transfected with CREG1 and pIRES vectors followed by drug 
selection for two weeks. Ten individual clones were selected and isolated from CREG1 
and pIRES transfected cells by cloning cylinders and transferred to a 24-well plate for 
further growth. Lifespan assay from four of each CREG1 and empty vector cell clones 
was performed as described in section 2.11. The calculated population doublings (PD) of 
CREG1 and vector control clones were obtained from over three months in culture on 
drug selection. At the end of the lifespan assay, the PD from three of the vector control 
clones exceeded 60 and the growth rate seemed to increase constantly, whereas three of 
CREG1 clones had PD ≤ 50 (Figure 13). The effect of CREG1 on stably transfected 
clones over a period of time seemed to slow growth compared with pIRES empty vector 
but did not induce growth arrest of the cells because they maintained their initial growth 
rate. To detect if CREG1 overexpressing cells induce a senescence-like phenotype, 
senescence-associated β-galactosidase staining was examined in pIRES- and CREG1-
expressing MDAH087-1 clones from passage 6 (Figure 14). CREG- expressing clones 
did not have higher activity of senescence-associated β-galactosidase than cells from 
vector control clones except clone no. 8 (8C8), which had high senescence-associated β-
galactosidase activity. This might be due to clonal variation and a higher spontaneously 
induced senescence of MDAH087-1 clone 8 fibroblasts. The protein level of CREG1 in 
pIRES and CREG1 expressed clones is shown in Figure 15.  
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Figure 13. Lifespan analysis of CREG1 overexpressing immortal cells. The population 
doublings of MDAH087-1 from pIRES and CREG1 expressing clones were calculated 
from cell number counted every week over a period of 105 days in culture.  
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3.4.3    CREG1 overexpression slows cell growth in cancer cell lines 
To confirm the negative growth effects of CREG1, cancer cell lines relevant to 
Li-Fraumeni Syndrome including osteosarcoma (U2OS;pRb+ and SaOS2;pRb-) (85) and 
fibrosarcoma (p53-deficient) (86) cell lines were investigated. The status of pRb, p16 and 
p53 in these cell lines as well as immortal LFS fibroblasts are shown in Table 2. Two µg 
of CREG1 and pIRES empty vectors were transfected into osteosarcoma U2OS (pRb+) 
and SaOS2 (pRb-) cells and fibrosarcoma HT1080 cells followed by drug selection (0.5 
µg/ml puromycin in standard culture media) for one week. Cell proliferation assays by 
cell counting were performed in the U2OS cells and the results showed that CREG1 
transfected U2OS cells grew slower cell than pIRES control cells (Figure 16). In 
addition, colony formation was examined in U2OS, SaOS2, and HT1080 cell lines 
transfected with CREG1 and pIRES control vectors followed by drug selection. 
Transfected cells were seeded at low density (500-5000 cells depending on cell lines) on 
10-cm culture plates in triplicate and cultured under drug selection for 2 weeks. The 
colonies were stained by Giemsa after two weeks in culture. The colonies (size≥ 1 mm) 
were counted and the relative colony number was calculated from normalization to the 
vector control. Overexpression of CREG1 decreased colony formation in U2OS and 
HT1080 cells and slight decreased colony formation in SaOS2 cells (Figure 17). 
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Table 2. The status of pRb, p16 and p53 in cell lines studied. LFS; Li-Fraumeni 
Syndrome immortal fibroblasts, U2OS and SaOS2; osteosarcoma, HT1080; fibrosarcoma 
cell lines. 
 
  
Cell line pRb p16 p53 
LFS 
MDAH041 
MDAH087 
MDAH172 
MDAH174 
 
Expressed 
Expressed 
N/A 
N/A 
 
No expression  
No expression  
N/A 
N/A 
Gene mutation 
Codon 184/ FS stop 
Codon 248 MS Arg-Trp 
Codon 175 MS Arg-His 
Codon 175 MS Arg-His 
U2OS Expressed  No expression Expressed  
SaOS2 No expression  Expressed  No expression  
HT1080 Expressed No expression Gene mutation  
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Figure 16. Cell growth assay of U2OS cells stably transfected with CREG1 and pIRES 
empty vectors. CREG1 overexpression slows cell growth in U2OS cells. After stable 
transfection, 1000 cells were seeded into a 24-well plate in triplicate and cell number was 
counted every 2 days. The data point with the standard deviation shows the result from a 
representative experiment. The experiments were repeated twice.  
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Figure 17. Colony formation assay of U2OS, HT1080, and SaOS2 cell lines. Cells were 
seeded as indicated (500-5000 cells) in triplicate and cultured for two weeks. The bar 
graphs demonstrate the relative colony number normalized with control empty vector. 
The error bars are standard deviation from at least two independent experiments. 
CREG1-overexpressing cells reduce colony number relative to vector control in U2OS 
and HT1080 cell lines and slightly decrease colony number in SaOS-2 cells. (** P<0.01; 
* P<0.05) 
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3.5 Analysis of CREG1 protein; glycosylation modification, cellular localization, 
and interacting proteins 
CREG1 was initially identified by the yeast two-hybrid method for proteins that 
interact with TATA-binding protein (TBP) in the Drosophila cDNA library (67). It was 
also shown to bind TBP and Rb family pocket proteins, pRb, p107 and p130 in vitro by 
GST pull down assay by the same group. CREG1 is a glycoprotein which contains three 
N-glycosylation sites (65). To determine whether there were glycosylated forms of 
CREG1 in our cells, we treated cell lysates from MDAH087-1 cells that overexpressed 
CREG1 with peptide-N-glycosidase F (PNGaseF) (BioLabs) following the 
manufacturer’s instructions. Western blot analysis of PNGaseF treated cell lysates 
demonstrated a deglycosylated form of CREG1 as shown in Figure 18. The size of 
CREG1 protein changed from glycosylated forms (~25-30 kD) to single form of protein 
(~20 kD), the predicted size of the protein calculated from amino acid sequence. 
To further investigate the localization of CREG1 within the cells, cytosolic and 
nuclear fractions from CREG1 stably transfected-MDAH087-1 cell clones were prepared 
and analyzed by western blotting. As shown in Figure 19, CREG1 was not observed in 
the nuclear fraction but mainly found in the cytosolic fraction. Nevertheless, detection of 
the majority of CREG1 in the cytosol does not exclude the possibility that CREG1 could 
function in the nucleus to antagonize the transcriptional activity of E2F and interact with 
TATA binding protein and Rb family pocket proteins, as revealed by Veal et al. (67). It is 
possible that the amounts of CREG1 present in the nucleus may be below the sensitivity 
of detection or that it accumulates in the nucleus under specific cellular conditions. 
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To investigate CREG1-interacting proteins, coimmunoprecipitation was 
performed in MDAH087-1 cell clones stably expressing CREG1 and control pIRES 
vectors. The concept of this method is to use the antibody targeting the protein of interest, 
which binds to the antigen or the target protein that may form the complex with its 
binding partners in the intact cell lysate. The immunocomplex is then analyzed for its 
known or unknown binding proteins. The antibodies of known CREG1 interacting 
proteins including CREG1, IGF2R and pRb were used in coimmunoprecipication (co-IP) 
experiments followed by western blot analysis. CREG1 was observed to directly interact 
with IGF2R by this method. However, we did not observe direct interaction between 
CREG1 and pRb by coimmunoprecipitation assay (Figure 20). Nevertheless, there are 
several aspects of concern regarding this assay, including the specificity of the antibody 
to the antigen (protein of interest), exposure of binding sites, and the tightness of the 
interaction with the proteins to be detected.  
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- PNGaseF       + PNGaseF 
 
Glycosylated CREG1 
Deglycosylated CREG1              
8V1 = MDAH087-1 pIRES stably transfected clone 1 
8C1 = MDAH087-1 CREG1 stably transfected clone 1 
8C8 = MDAH087-1 CREG1 stably transfected clone 8 
 
Figure 18. Deglycosylation of CREG1. Total cell lysate from MDAH087-1 cell clones 
stably expressing vector control (8V1) and CREG1 (8C1 and 8C8) at passage 19 were 
treated and untreated with PNGaseF followed by western blotting. Treatment with 
PNGaseF deglycosylates CREG1.  
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3.6 Discussion  
The goal of this study was to investigate the role of CREG1 in cellular 
immortalization and senescence. This gene was identified from the gene expression 
profiling analysis (56) of genes and pathway changes during cellular immortalization and 
senescence in Li-Frameni Syndrome fibroblasts harboring p53 mutations. CREG1 is one 
of the genes that was shown to be downregulated during immortalization and upregulated 
after 5-aza-dC-induced senescence. CREG1 was demonstrated to be a negative regulator 
of E2F transcription factors that antagonizes the ability of E1A to transform the cells to 
be tumorigenic (67). This background information indicated that CREG1 was an 
interesting candidate gene for study.  
We then investigated the role of CREG1 in cellular senescence in immortal LFS 
and related cancer cell lines. Verification of CREG1 expression in four spontaneously 
immortalized LFS cell lines used in microarray study and additional two LFS cell lines 
revealed that CREG1 levels decreased in immortal fibroblasts compared with each 
precrisis counterpart cell strain and its expression was upregulated in replicative and 5-
aza-dC-induced senescence of fibroblasts. Analysis of the CREG1 promoter identified a 
CpG island that was highly methylated in MDAH041, partially methylated in 
MDAH087-1 and poorly methylated in MDAH087-10 immortal fibroblasts. It is possible 
that the two alleles of CREG1 in MDAH087-1 and MDAH087-10 are differentially 
methylated reflecting the intermediate expression level of CREG1 in these cells when 
compared with heavily methylated promoters from MDAH041. In addition, CREG1 is 
located at the 1q24.1 region and it has been shown that chromosome 1q carries genes 
altered in cell lines assigned in complementation group C, which is involved in cellular 
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senescence (87). We demonstrated for the first time that CREG1 expression is 
epigenetically silenced by promoter methylation in immortal fibroblasts and this may 
contribute to cellular immortalization. 
To examine whether CREG1 can induce cellular senescence, CREG1 and pIRES 
empty vectors were stably transfected into two immortal LFS cell lines, MDAH041 and 
MDAH087-1, which express the lowest levels of CREG1. We found that CREG1 
overexpression in immortal LFS cells resulted in slow cell growth compared with control 
pIRES transfected cells. These results support the growth suppression function of CREG1 
from previous studies (69, 70). The negative growth effects of CREG1 were also 
observed in cancer cell lines including U2OS osteosarcoma (wild-type p53) and HT1080 
fibrosarcoma (p53-deficient). However, the growth suppression effect of CREG1 was 
lower in SaOS2 cells, another osteosarcoma cell line which has no pRb expression, 
compared to two other cell lines studied that express pRb protein. In addition, the 
expression level of CREG1 in this cell line, SaOS2, seems to be higher than others. This 
may indicate that the growth suppressive function of CREG1 depends on the Rb 
signaling pathway. Moreover, analysis of the lifespan (population doubling) of 
MDAH087-1 immortal cells expressing CREG1 revealed that CREG1 expressing cells 
continued to grow at a slower rate than empty vector expressing cells. Nevertheless, we 
did not observe the induction of cellular senescence in cells transfected with CREG1 
alone as judged by cellular morphology or the senescence-associated β-gactosidase assay. 
Although, we observed the slight increase of senescent cells in MDAH087-1 cell clones 
expressing CREG1 when compared with vector control clones (Figure 14), this may not 
conclude that those senescent cells caused by CREG1 expression but spontaneously 
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senescing, because we also observed the basal level of senescent cells in cells transfected 
with vector control. This can be due to stress associated with cell culture conditions and 
changes of pH in the β-galactosidase staining assay which influence an increase of β-
galactosidase activity (10, 88). Despite the epigenetically downregulation of CREG1 may 
be one of the steps during immortalization, the ectopic expression of CREG1 in immortal 
LFS and cancer cells was not sufficient to induce senescence. This can be partly due to 
the absence some other partner proteins associated with CREG1 function or proteins that 
regulate CREG1 in some way.  
Cell fractionation analysis of immortal cells overexpressing CREG1 showed that 
the majority of CREG1 is found in the cytosolic fraction. However, no previous study has 
clearly elucidated the localization of CREG1 in the nucleus as expected for a 
transcriptional repressor. It is possible that the signaling pathway involved in the negative 
growth effects of CREG1 occurs outside the nucleus. The putative receptor of CREG1 is 
IGF2R, the scavenger transmembrane protein that plays a role in regulation of insulin-
like growth factor II (IGF-II) endocytosis. Supporting this observation, a study from Han 
et al. showed that CREG1 plays a role in the inhibition of smooth muscle cells migration 
by mediating IGF-II endocytosis via the IGF2R receptor (74). It is therefore possible that 
the growth suppressive function of CREG1 may depend on the IGF2R-IGF2 signaling 
pathway. We examined CREG1 interacting proteins by coimmunoprecipitation using 
CREG1 antibody and found that CREG1 physically interacts with IGF2R. However, we 
did not observe the interaction of CREG1 and Rb pocket proteins as demonstrated by 
Veal et al. 1998, who used an in vitro GST pull-down assay. To further investigate 
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CREG1 interacting proteins, an alternative and more sensitive technology such as mass-
spectrometry may be needed to identify proteins that interact with CREG1.  
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CHAPTER 4 
CREG1 ENHANCEMENT OF P16INK4a IN GROWTH SUPPRESSION AND 
SENESCENCE 
4.1 Summary 
 The functional analysis of CREG1 in immortal LFS and related cancer cell lines 
revealed the growth suppression function of CREG1. However, CREG1 overexpression 
did not directly induce senescence. We hypothesized that CREG1 function may depend 
on the phosphorylation status of pRb which is phosphorylated by cyclin/CDK complex. 
p16INK4a, a CDK 4/6 inhibitor, is an upstream regulator of Rb phosphorylation and plays 
an important role in cellular senescence. We found that p16INK4a expression was 
downregulated in immortal LFS fibroblasts and its expression was epigenetically 
regulated by promoter hypermethylation (56). In addition, p16INK4a is not expressed in 
U2OS and HT1080 cell lines. SaOS2 cell line expresses p16INK4a but not pRb. 
Interestingly, coexpression of CREG1 and p16INK4a in immortal LFS, U2OS and HT1080 
cell lines induced a senescence-like phenotype including changes of cell morphology, 
decreased cell growth, increased staining of senescence-associated β-galactosidase, 
decreased transcriptional activity and expression levels of cyclin A and B, regulators of 
cell cycle progression. We further investigated the role of Rb-family members, pRb, p107 
and p130 in cellular senescence induced by cooperation between CREG1 and p16 by 
using lentivirus-mediated knockdown of each Rb family protein in U2OS cells. p16 alone 
or coexpression of CREG1 and p16 induced senescence in U2OS cells stably infected 
with lentivirus-mediated knockdown of p107, p130 and non-silencing control cells. 
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However, this effect was diminished in Rb knockdown cells. This indicates that pRb is 
critical in cellular senescence induced by coexpression of CREG1 and p16.  
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4.2 Coexpression of CREG1 and p16INK4a has a great effect to suppress cell 
growth 
 To investigate whether coexpression of CREG1 could enhance the effect of p16-
induced senescence in immortal LFS fibroblasts, U2OS and HT1080 cell lines were used. 
Plasmids containing CREG1 and p16INK4a were cotransfected into these cell lines, alone 
or in combination using the empty vectors to balance the amount of transfected DNA. 
Cells were selected using double drug selection in all cases: puromycin (0.5 µg/ml) and 
G418 (200 µg/ml), to ensure similar transfection efficiency. Control untransfected cells 
died after 3 days of drug selection. After 5 days of selection, U2OS cells were expanded 
for growth and senescence. Cell cycle analysis by flow cytrometry showed an increase of 
cells in G0-G1 arrest and a decrease of S phase cells in cells cotransfected with CREG1 
and p16 compared to cells transfected with either CREG1 or p16 alone (Figure 21 and 
Figure 22). The data were obtained from three independent experiments. The histograms 
are shown from flow cytometry of representative experiments. There was no obvious sign 
of apoptosis (sub-G1 peak of PI histogram) observed from the cell cycle analysis results 
(Figure 22). The additional independent results of cell cycle analysis by flow cytrometry 
(histograms of cell populations) are shown in Appendix 1 and 2. 
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Figure 22. Histograms of cell cycle analysis by flow cytometry of U2OS cells transfected 
with CREG1 and p16 from the representative experiment. Cells were analyzed at day 5 
after drug selection. The numbers indicate the percent of cell population in G0-G1, S and 
G2-M phases. 
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To confirm the growth inhibition upon CREG1 and p16 coexpression, a colony 
formation assay was performed after stable transfection. U2OS cells were transfected 
with 2 µg each of CREG1 and p16, alone or in combination followed by double drug 
selection at 48h after transfection for 5 days. Transfected cells were trypsinized and 
seeded at low density (2000 cells in 10-cm cultured plates) in triplicate and cultured 
under drug selection for 2 weeks. The colonies were stained with Giemsa and the colony 
number was counted and compared to the vector control. As shown in Figure 23, colony 
formation was inhibited in cells cotransfected with CREG1 and p16 more than cells 
transfected with p16 or CREG1 alone. The results were obtained from three experiments. 
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4.3 CREG1 enhances p16INK4a-induced senescence: cell morphology changes and 
senescence-associated β-galactosidase staining 
The senescent-like phenotype can be observed by changes of cell morphology 
(large and flat cells) and an increase of senescence-associated β-galactosidase activity at 
pH 6. These characteristics, as well as the growth arrest phenotype, were used as 
indicators of senescent cells in this study. U2OS cells were transfected with CREG1 and 
p16, alone and in combination, followed by double drug selection for 5 days as 
mentioned above. In p16-transfected cells, and more so in cells cotransfected with 
CREG1 and p16, we observed cell characteristics indicative of senescence as shown in 
Figure 24 (cell morphology) and Figure 25 (senescence-associated β-galactosidase 
staining) at day 5 after drug selection. Although it was shown previously that p16 
overexpression alone induces cellular senescence in this cell line, U2OS, we showed here 
that coexpression of CREG1 with p16 induced an even stronger effect than p16 
expression alone.  
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Figure 24. Cell morphology of U2OS cells cotransfected with CREG1 and p16, alone 
and in combination. Transfected cells were β-galactosidase stained and photographed at 
day 5 after selection. The pictures show two different fields on the culture plate from the 
representative experiment. Scale bar is 200 µm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figur
transf
perce
analy
contr
comb
 
 
 
 
 
 
 
0
10
20
30
40
50
60
70
Pe
rc
en
t β
‐g
al
 st
ai
ni
ng
e 25. Sene
ected with 
nt of SA-β-
sis was perf
ol (P<0.01)
ination of C
Vector
scence-asso
CREG1 and
gal stained 
ormed to te
. Student’s 
REG1 and p
CR
SA-β
ciated β-ga
 p16, alone
(blue) cells
st the differ
t-test was 
16 on colon
77 
EG1
gal Stainin
lactosidase 
 and in com
 from three
ences of pe
performed 
y formation
p16
g
(SA-β-gal)
bination. T
 independen
rcent staine
to compare
. ** P<0.01
**
CREG1+p1
staining of
he bar grap
t experimen
d cells relat
 the effect
 
6
 U2OS cell
hs show th
ts. ANOVA
ive to vecto
 of p16 an
s 
e 
 
r 
d 
78 
 
 
 We also examined the effect of CREG1 and p16 coexpression in cellular 
senescence in the HT1080 fibrosarcoma cell line. As shown in Table 2, this cell line is 
p53-deficient, does not express p16 and contains intact pRb protein. Coexpression of 
CREG1 and p16 in this cell line was done similarly to U2OS cells as described above. 
Interestingly, the effect of CREG1 and p16 on cellular senescence was also observed in 
this HT1080 cell line. Coexpression of CREG1 and p16 showed an increase in 
senescence-associated β-galactosidase staining and cell morphology changes 
characteristic of senescent cells (Figure 26 and Figure 27). These results indicate that the 
effect of CREG1 and p16 coexpression on cellular senescence does not depend on the 
intact p53 protein.  
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Figure 26. Cell morphology of HT1080 cells transfected with CREG1 and p16, alone 
and in combination. Cells were split for senescence-associated β-galactosidase staining at 
the same cell number after two weeks of drug selection. The pictures show two different 
fields on the plate from the representative experiment. Scale bar is 200 µm. 
 
 
 
 
 
 
 
Figure 27. Senescence-associated β-galactosidase staining of HT1080 cells 
coexpresssing CREG1 and p16. The bar graphs show the percent of β-gal stained (blue) 
cells from the representative experiment. 
Vector CREG1 p16 CREG1+p16 
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 In addition, we also observed the additive effect of CREG1 and p16 to induce 
senescence in an immortal LFS cell line. The MDAH041 cell line was transfected with 2 
µg each of CREG1 and p16, alone and in combination followed by double drug selection. 
After two weeks of selection, cells were trypsinized and lifespan analysis of stably 
transfected cells as well as MDAH041 untransfected cells was performed. In this assay, 
cells were seeded at 1x105 cells in a 10-cm culture plate and the cell number was counted 
to calculate the population doubling by applying log2 to the total cell number after one 
week in culture. The cells were then re-seeded at the same amount and the population 
doublings were calculated. The cell morphology of MDAH041 transfected with CREG1 
and p16 at day 5 after seeding for the lifespan assay is shown in Figure 28. The lifespan 
analysis showing the population doublings of MDAH041 cells over a month in culture is 
shown in Figure 29. Unexpectedly, cells stably expressing p16 grew at a similar growth 
rate as CREG1-expressing cells. It is possible that these data indicate the outgrowth of 
cells expressing lower amount of the proteins of interest, in this case CREG1 and p16, 
which would influence the results of this experiment. We speculate that culture of these 
cells over time may cause loss of the growth suppression effect of CREG1 and p16, alone 
and in combination. 
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Figure 29. Lifespan analysis of MDAH041 cells stably transfected with CREG1 and p16, 
alone and in combination. The population doublings are calculated from total cell number 
counted every week. Coexpression of CREG1 and p16 decreased the population doubling 
compared to CREG1 and p16 expression alone. 
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4.4 The effect of CREG1 and p16 coexpression on cell cycle regulator expression 
 To investigate the effect of CREG1 and p16 on cell cycle control, the expression 
of genes involved in cell cycle progression were examined by western blotting. U2OS 
cells were transfected with CREG1 and p16 as mentioned above and the protein levels of 
Rb family pocket proteins and cyclins were determined after 5 days of drug selection. We 
found that cells coexpressing CREG1 and p16 showed a marked decline in protein levels 
of cyclin A and B (Figure 30). In addition, the protein levels of pRb/p105 and RbL1/p107 
were decreased whereas RbL2/p130 expression was unchanged. The same results were 
obtained from HT1080 cells cotransfected with CREG1 and p16 (Figure 31). 
Additionally, as mentioned in section 4.2, no differences were detected in Parp protein 
cleavage, which is an indicator of apoptosis. The western blotting of Parp protein is 
shown in Appendix 3 (Exp#38). Fragments of cleaved Parp are observed in all 
transfected conditions, which may be caused by stressful cell culture conditions or the 
effect of drug selection. 
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Figure 31. Western blot analysis of HT1080 cell line transfected with CREG1 and p16. 
The cell lysates were harvested at day 5 after drug selection. CREG1 and p16 
coexpression reveals a marked decrease of cyclin A and B whereas cyclin D expression is 
still retained. Expression of pRb and p107 are downregulated and p130 is still expressed 
in CREG1 and p16 cotransfected cells.The results shown were obtained from two 
independent experiments. 
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4.5 CREG1 and p16INK4a coexpression inhibits the expression of cyclin A at the 
transcriptional level 
We found that coexpression of CREG1 and p16 in U2OS and HT1080 cell lines 
greatly repressed cyclin A and B protein expression levels. The expression level of cyclin 
A mRNA was also determined by Q-RT PCR. Total RNA was isolated and cDNA was 
prepared from U2OS cells transfected with CREG1 and p16 at day 5 after drug selection. 
The mRNA levels of cyclin A2 were examined (Figure 32) and were consistent with the 
protein levels. 
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Figure 32. The expression of cyclin A2 by Q-RT-PCR in U2OS cells transfected with 
CREG1 and p16, alone and in combination. The data represents the average relative 
expression level of cyclin A to the vector control from two independent experiments. 
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To further examine the effect of CREG1 with and without cotransfection of p16 
on cyclin A expression, we constructed a cyclin A reporter vector containing a fragment 
of cyclin A promoter driven luciferase reporter gene. The schematic of the cyclin A2 
promoter fragment used for the luciferase reporter assay is shown in Figure 33 (83). The 
CCRE site on the cyclin A2 promoter is mediated by Rb pocket proteins and is activated 
by the E2F transcription factor. Mutation of this site abrogates the promoter activity (89).  
In addition, the CRE element on the promoter was revealed to regulate the promoter 
activity and its expression level of cyclin A2. Previous studies by Ahmed-Choudhury et 
al. 2005 (83) and Fajas et al. 2001 (90) demonstrated that p120E4F, a transcription factor, 
binds to the CRE element of the cyclin A2 promoter and negatively regulates the 
promoter activity of cyclin A2. We then tested if the effect of CREG1 and p16 
overexpression, alone and in combination, may depend on the transcriptional repression 
of the CRE site through p120E4F. The cyclin A2Δ reporter vector was constructed as 
described in section 2.10. The schematic of this reporter is shown in Figure 33. 
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A. 
 
B. 
 
Figure 33. The schematic of cyclin A2 promoter reporters. A. diagram of cyclin A2 
luciferase reporter containing wild-type cyclin A2 promoter. B. diagram of cyclin A2 
luciferase reporter with deletion of CRE site (cyclin A2Δ). 
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U2OS cells (4x105 cells in 6-well culture plate) were transfected with 2 µg each of 
CREG1 and p16 expression vectors, alone and in combination as mentioned above, 
followed by double drug selection at 48h after transfection for 3 days. At day 4 of drug 
selection, 2 µg of the cyclin A reporter and 0.1 µg TK-Renilla vector were transfected 
into CREG1 and p16 transfected cells. Forty hours after reporter transfection, cells were 
harvested for luciferase assay (dual-luciferase reporter assay system, Promega) to 
measure the activity of luciferase and renilla for normalization. Consistent with a 
decrease of the protein and mRNA level of cyclin A2, coexpression of CREG1 and p16 
showed a significant decrease of transcriptional activity of cyclin A2 wild-type promoter 
(Figure 34). On the other hand, the activity of the cyclin A2Δ reporter was lower 
compared to the cyclin A2 wild-type promoter and overexpression of CREG1 and p16 
did not decrease the activity of this reporter compared to the vector control (Figure 35). 
This indicates that the CRE element on cyclin A2 promoter plays a role in the 
transcriptional repression mediated by CREG1 and p16. However, since the luciferase 
activity of this reporter is lower than the wild-type promoter, the deletion of the CRE 
element may affect the overall activity of the cyclin A2 promoter. 
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Figure 35. The cyclin A2Δ reporter activity in U2OS cells cotransfected with CREG1 
and p16. The bar graphs show the luciferase activity obtained from luciferase/renilla ratio 
from two independent experiments.  
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4.6 The effect of CREG1 and p16 on E2F1 transcriptional activity 
 CREG1 was previously shown to inhibit the transcriptional activity of the E2F 
transcription factors (67). In this study, we found that coexpression of CREG1 and p16 
greatly inhibits the transcriptional activity of the cyclin A promoter which contains an 
E2F transcription factor binding site. The expression of cyclin A is regulated by binding 
of E2F (89).To further investigate the function of CREG1 and its enhancement of p16 in 
transcriptional repression, we examined the activity of the E2F reporter obtained by 
cloning four E2F binding sites driven by TATA promoter into a luciferase gene reporter 
as well as the activity of the E2F1 promoter reporter in U2OS cells transfected with 
CREG1 and p16, alone and in combination. In the E2F-TA (four E2F binding sites driven 
by TATA promoter) luciferase reporter assay, U2OS cells were transfected with vector 
control, CREG1 and p16, alone and in combination as described in section 2.2 followed 
by double drug selection for 3 days. U2OS cells (4x105 cells) were seeded into 6-well 
culture plate in tripicate prior to transfection. One µg of E2F-TA reporter plasmid, 0.5 µg 
of E2F1/CMVexpression vector, and 0.1 µg of TK-renilla plasmid for internal control, 
were transfected into CREG1 and p16 transfected cells at day 4. The cell lysate for 
luciferase assay were harvested at 40 h after reporter transfection using dual-luciferase 
reporter assay system kit (Promega) according to the manufacturer’s instruction. 
However, we did not observe the inhibition of E2F activity from this experiment after 
repeating three times (Figure 36). Moreover, the activity of the E2F1 promoter reporter 
that was examined similar to the E2F-TA reporter described above was not significantly 
different among vector control and CREG1 and p16 combinations (Figure 37). 
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Figure 36. The E2F-TA reporter activity of U2OS cells transfected with CREG1 and 
p16. The bar graphs show the average luciferase activity (the ratio of luciferase/renilla) in 
triplicate from two independent experiments. ANOVA analysis was performed to test the 
differences of luciferase activity relative to vector control (P=0.04). 
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Figure 37. The E2F1 promoter reporter activity in U2OS cells transfected with CREG1 
and p16. The bar graphs show the average luciferase activity (the ratio of 
luciferase/renilla) in triplicate from three independent experiments. ANOVA analysis was 
performed to test the differences of luciferase activity relative to vector control (P= 0.2). 
 
 
 
 
 
 
 
 
 
 
 
96 
 
 
4.7 The effect of Rb family members on cellular senescence induced by CREG1 
and p16INK4a coexpression 
 The retinoblastoma tumor suppressor (pRb/p105) and its related proteins, 
RbL1/p107 and RbL2/p130, share similar structures (pocket protein) and biological 
functions. They mainly function to bind to and negatively regulate the transcription of the 
E2F transcription factor. Different pocket proteins associate with and inhibit the 
transcriptional activity of different E2F isoforms. While pRb interacts and inhibits the 
transcriptional activator E2F, including E2F1, E2F2 and E2F3, p107 and p130 interact 
with the transcriptional repressor E2F4 and E2F5 (79). 
 To investigate whether the effect of CREG1 on enhancement of p16 requires pRb, 
p107 or p130, shRNA mediated knockdown of each pocket protein using a lentiviral 
system was performed in U2OS cells. U2OS cells were infected with lentivirus targeting 
each of the Rb members or a non-silencing control. The infected U2OS cells were 
selected with puromycin (0.5 µg/ml). Uninfected U2OS cell, non-silencing and each of 
the Rb family protein knockdown cells were then transfected with CREG1/pcDNA3.1-
hygromycin and p16/pcDNA3.1-neo. To ensure the transfection efficiency, the selection 
of transfected cells was done using 3 drugs: puromycin for the lentivirus, hygromycin for 
CREG1 and G418 for p16. Stably transfected cells were analyzed by flow cytometry for 
cell cycle analysis, detection of senescence by senescence-associated β-galactosidase 
staining and western blotting after 5 days of selection. The cell morphology and 
senescence-associated β-galactosidase staining of Rb knockdown U2OS cells transfected 
with CREG1 and p16 is shown in Figure 38-42. The quantification of SA-β gal staining 
of non-silencing and each of Rb member knockdown U2OS cells transfected with 
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CREG1 and p16, alone and in combination, at day 5 after drug selection is shown in 
Figure 43. We found that while expression of p16 alone and in combination with CREG1 
seemed to be able to induce senescence in uninfected U2OS, non-silencing, p107, and 
p130 knockdown cells, knockdown of Rb showed less of a senescent phenotype than 
others considering cell morphology and senescence-associated β-galactosidase staining. 
We detected the expression of cell cycle regulator proteins by western blot analysis of 
lentiviral-mediated Rb knockdown, non-silencing and U2OS cells transfected with 
CREG1 and p16. Stably transfected cells were harvested for western blotting at day 5 
(Figure 44) and day 10 (Figure 45) after three drug selection. The knockdown efficiency 
of each Rb family member was confirmed. Consistent with the cell morphology 
observed, we found that pRb knockdown U2OS cells, when overexpressed with p16 
alone and in combination with CREG1, showed less decrease of cyclin A and cyclin B 
compared with non-silencing control, p107 and p130 knockdown cells. In addition, 
whereas the protein levels of p107 were shown to be decreased in uninfected U2OS and 
non-silencing cells transfected with CREG1 and p16, which was observed previously in 
senescent cells, the levels of p107 and p130 in pRb knockdown cells seemed to be 
increased. This might indicate the compensation of p107 and p130 in Rb knockdown 
cells. However, while we observed the effect of Rb-family knockdown U2OS cells 
transfected with CREG1 and p16 from cell morphology changes and analysis of protein 
expression levels, cell cycle analysis by flow cytometry did not reveal conclusive results 
obtained from three experiments (data not shown).  
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Figure 43. Senescence-associated β-galactosidase staining of lentivirus-mediated non-
silencing and Rb member knockdown U2OS cells transfected with CREG1 and p16. 
Cells were stained for SA-β gal activity at day 5 after drug selection. The bar graphs 
show the average percent of stained cells counted from 5 different fields on cell culture 
plates from two independent experiments.  
 
  
0
5
10
15
20
25
30
35
40
45
50
Ve
ct
or
CR
EG
1
p1
6
CR
EG
1+
p1
6
Ve
ct
or
CR
EG
1
p1
6
CR
EG
1+
p1
6
Ve
ct
or
CR
EG
1
p1
6
CR
EG
1+
p1
6
Ve
ct
or
CR
EG
1
p1
6
CR
EG
1+
p1
6
Non‐silencing p107‐KD p130‐KD pRb‐KD
Pe
rc
en
t β
‐g
al
 st
ai
ni
ng
SA‐β galactosidase staining
104 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 44. Western blot analysis of lentivirus-mediated Rb members knockdown U2OS 
cells transfected with CREG1 and p16, alone and in combination. Cells lysates were 
harvested at day 5 after selection. Cyclin A expression are less decreased in pRb-
knockdown cells when transfected with p16 and combination of CREG1 and p16. 
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Figure 45. Western blot analysis of lentivirus-mediated Rb members knockdown U2OS 
cells transfected with CREG1 and p16, alone and in combination. Cells lysates were 
harvested at day 10 after selection. Cyclin A and cyclin B expressions are less decreased 
in pRb-knockdown cells when transfected with p16 and combination of CREG1 and p16. 
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4.8 Discussion 
Abrogation of genes and pathways regulating cellular senescence can cause cells 
to become immortal leading to additional genetic and epigenetic changes to develop in 
cancers. Cellular senescence is one of the tumor suppressor mechanisms, besides 
apoptosis, which is responsible for preventing cells from uncontrolled propagations. The 
senescence can occur by telomere dependent (replicative senescence) and telomere-
independent (oncogene- or stress-induced senescence) mechanisms.  
Several studies were pursued to understand more knowledge of senescence 
mechanism in order to provide additional benefits for better management of human 
cancers. An attempt to identify new regulators of cellular senescence has been done in the 
Tainsky lab using spontaneously immortalized fibroblasts from Li-Fraumeni Syndrome 
patients as a study model. Taking advantage of these spontaneously immortal cell lines as 
opposed to other immortal cells induced by either viral oncoprotein such as SV40 large T 
antigen or chemicals may provide fewer side effects that may cause by those factors.  
In this thesis research, CREG1 was chosen as a candidate gene for investigation 
because its involvement in cellular senescence appeared to be due to its function in cell 
cycle regulation regulating E2F transcription activity (67) and its negative growth effect 
in cancer (69) and vascular (71) cells. The method that we used to examine the role of 
CREG1 in cellular senescence was stable expression of CREG1 in immortal LFS and 
cancer cell lines followed by investigating growth and lifespan. We found that 
overexpression of CREG1 alone in immortal LFS and cancer cell lines did not induce 
cellular senescence but was able to slow cell proliferation. Because the cells we used 
have lost the function of p16INK4a and because CREG1 was shown to interact with Rb 
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family pocket proteins thus inhibiting the transcription of E2F transcription factor, we 
then hypothesized that CREG1 might be involved in a p16INK4a-pRb-dependent 
senescence pathway. p16INK4a, a CDK inhibitor of pRb phosphorylation, is one of the 
tumor suppressor genes that is commonly disrupted in immortal cells and some cancer 
cells. p16INK4a expression is also upregulated in senescent fibroblasts (63, 91, 92). 
Several studies showed that ectopic expression of p16INK4a caused cell cycle arrest and 
senescence in immortal LFS (54) and human cancer cells including U2OS cell line (80, 
93-95) and these effects depended on the normal function of pRb.  
Interestingly, we discovered that coexpression of CREG1 and p16 in U2OS cells 
(pRb+/p16-/p53+) had a greater effect on cell growth inhibition, induction of cell cycle 
arrest, inhibition of colony formation, and the induction of senescence than expression of 
CREG1 or p16 alone. Consistent with its activity to induce cell cycle arrest, cells 
cotransfected with CREG1 and p16 showed a marked decrease of cyclin A and B 
expression. The decrease expression of cyclin A was regulated at the transcriptional level. 
We also found that expression of pRb and p107 decreased in p16 and CREG1+p16 
transfected cells, but p130 expression was unchanged. The changes of Rb pocket proteins 
in our study were consistent with those shown by Helmbold et al who showed that p130 
accumulates and is important to maintain senescence and that pRb and p107 decrease in 
DNA damage and p16-induced senescence (96, 97). The decreased expression of pRb 
and p107 in senescent cells that we observed upon overexpression of p16 and 
combination of CREG1 and p16 were similar to those from other studies (12, 96, 98). 
However, the mechanism of pRb and p107 downregulation during senescence is poorly 
understood. It may be partly due to the unnecessary of pRb and p107 upon fully engaged 
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senescence. Moreover, cyclin A expression was shown to be downregulated in cellular 
senescence by p130 recruitment to the cyclin A promoter to repress transcription (96, 99, 
100). The enhancement of p16-induce senescence by CREG1, resulted in an increase of 
senescence-associated β-gal activity and other changes in cell cycle regulator proteins, 
was also observed in the HT1080 fibrosarcoma cell line, which is p53 deficient indicating 
that the additive effect of CREG1 in p16INK4a-induced senescence may be independent of 
p53. Because both p16-pRb and p53-p21 signaling pathways have been shown to play an 
important role in cellular senescence, this study demonstrated that cellular senescence can 
be engaged by p16 overexpression in p53-deficient cells indicating the independent role 
of these two pathways in senescence mechanism. Study by Vogt et al. also demonstrated 
that overexpression of p16 or p21 were sufficient to induce senescence-like phenotype in 
two of immortal LFS cell lines, MDAH041 and MDAH87 which harbor p53 mutation 
(54). The effect of p16- or p21-induced senescence was independent with each other, in 
other words, induction of senescence by p16 overexpression did not alter p21 expression 
and p21 induced senescence without the upregulation of p16 (54).  
Rb family pocket proteins, pRb, and its related protein p107 and p130, play an 
important role in suppressing cell growth by controlling cell cycle progression and 
chromatin condensation (101). p130 maintains cells in G0 and early G1 by binding and 
inactivating E2F4 and E2F4 which are repressor E2Fs. When cells progress through cell 
cycle, p130 is then replaced by p107 in mid to late G1 to bind to and inactivate E2F4 and 
E2F5. In late G1 and S phase, pRb is replaced to interact with and inhibit activator E2Fs, 
E2F1, E2F2, and E2F3 (reviewed in Macaluso M et al. (102)). Because different pocket 
proteins bind to and inhibit different isoforms of E2Fs thus modulate different phases in 
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cell cycle progression, we asked if the enhancement of p16-induced senescence by 
CREG1 involved particular Rb-family members. We used lentivirus-mediated gene 
knockdown to target each of Rb member in U2OS cells expressing all three pocket 
proteins. Cells stably infected with lentivirus-mediated knockdown were then transfected 
with CREG1 and p16, alone and in combination, to determine the effect of CREG1 and 
p16 coexpression in senescence induction. We found that expression of p16 and 
combination of CREG1 and p16 in p107- and p130-knockdown cells showed the 
senescence-like phenotype, as judged by cell morphology and senescence-associated β 
gal staining, similar to non-silencing and uninfected U2OS cells. However, the level of 
CREG1 and p16 combination or p16 alone-induced senescence in pRb knockdown cells 
was decreased. We observed more colonies of transfected cells formed after drug 
selection and fewer senescent cells in pRb knockdown cells with p16 and coexpression of 
CREG1 and p16. These results indicated that pRb but not p107 and p130 is required for 
the cellular senescence mechanism and that the enhancement of p16 induced senescence 
by CREG1 is dependent on the pRb signaling pathway. This observation is consistent 
with the study from Chicas et al. and Talluri et al. demonstrating that Rb has a unique 
role in cellular senescence that is nonredundant with other pocket proteins, p107 and 
p130, by repressing DNA replication as cells exit the cell cycle into senescence (103, 
104). That knockdown of p107 and p130 in cells used in our study (U2OS cells) resulted 
in induction of senescence-like phenotype by p16 and combination of CREG1 and p16 
expressions may indicate the redundant role of p107 and p130 because these two pocket 
proteins bind to and inhibit the same subset of repressor E2Fs. This finding is consistent 
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with study from Jacson et al. demonstrating the compensation of p107 with p130 loss 
upon DNA damaging agent-induced senescence (99).  
The senescent cells that were induced by the combination of CREG1 and p16 
overexpression were not insignificantly different compared with p16 expression alone in 
the experiments of lentivirus-mediated non-silencing and Rb member knockdown U2OS 
cells considering the senescence-associated β galactosidase staining,. This can be due to 
the complexity of lentivirus-mediated knockdown and cell culture stresses of using three-
drug selection. We also observed less transfection efficiency (more cell death after 
selection in all transfection conditions) in this experiment compared with the 
cotransfection of CREG1 and p16 in U2OS cells in early experiment.  
We demonstrated that coexpression of CREG1 and p16INK4a significantly 
inhibited cyclin A and B expression at the transcriptional level. We specifically 
investigated cyclin A2 (protein, mRNA, and promoter) and B1 (protein) because they are 
expressed in proliferating cells. Cyclin A and cyclin B are essential for S phase entry and 
G2 phase, respectively (105-107). Decreased expression of cyclin A and B in senescent 
cells was observed from other studies including senescence induced by DNA damaging 
agent and replicative senescence (96, 108), although it is not certain whether this 
downregulation is a cause or a consequence of growth arrest in cellular senescence. 
However, we did not observe downregulation of cyclin D in coexpression of CREG1 and 
p16INK4a-induced senescence. On the other hand, cyclin D1 was shown to be 
upregulated in senescent cells, and its expression has also been used as a marker of 
senescence (109-113) which was also observed in our study. An attempt to investigate the 
effect of CREG1 and p16 overexpression, alone and combination, on the transcriptional 
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activity of E2F using two reporter plasmids, E2F-TATA (four E2F binding sites driven 
by TATA promoter) and E2F1 promoter reporter, did not detect transcriptional repression 
by p16 or by coexpression of CREG1 and p16. This might be due to the complexity of 
the balanced amount of E2F transcription factor in the cell studies (U2OS cells). The 
activity of the E2F-TA reporter was undetectable without overexpression of E2F1 
transcription factor in the reporter assay. This overexpression of E2F1 may influence the 
transcriptional repression effects of CREG1 and p16 expression.  
Nevertheless, we cannot exclude the possibilities that the additive effect of 
CREG1 and p16 that was observed in this study may be due to the p16INK4a-pRb 
signaling pathway and that CREG1 is part of this mechanism, or that CREG1 functions 
through other pathway(s) such as its regulation of IGF-II signaling (74) which may 
promote the p16INK4a-pRb signaling-induced senescence. More studies are needed to 
further investigate whether involvement of CREG1 in p16INK4a-induced senescence is 
due to its transcriptional repressor activity. Chromatin immunoprecipitation method 
would be able to address that question. In addition, to further elucidate the role of 
CREG1 in cellular senescence involved in p16-pRb signaling pathway, depletion of 
CREG1 and p16 expression in normal diploid fibroblast or precrisis fibroblasts by 
lentivirus-mediategd gene knockdown following the analysis of lifespan can provide 
more evidences on the necessity of these two genes in cellular senescence.  
In summary, we demonstrated that CREG1 is regulated by epigenetic mechanisms 
and its downregulation may be one of the important steps in cellular immortalization. 
Ectopic expression of CREG1 in immortal and cancer cells lacking endogenous 
p16INK4a results in decreased cell proliferation but does not induce senescence. 
112 
 
 
Importantly, CREG1 enhances p16INK4a-induced senescence. Analysis of how CREG1 
and its enhancement of p16INK4a-induced senescence may provide better understanding 
of cellular immortalization, an early step in human tumorigenesis, and could improve 
treatment or prevention of cancer at early stage. 
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APPENDIX 
 Flow cytometry 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 1. Histograms of cell cycle analysis by flow cytometry of U2OS cells 
transfected with CREG1 and p16. Cells were analyzed at day 5 after drug selection. 
The numbers indicate the percent of cell population in G0-G1, S and G2-M phases. 
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Appendix 2. Histograms of cell cycle analysis by flow cytometry of U2OS cells 
transfected with CREG1 and p16. Cells were analyzed at day 5 after drug selection. 
The numbers indicate the percent of cell population in G0-G1, S and G2-M phases. 
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ABSTRACT 
CREG1 AND ITS ENHANCEMENT OF P16INK4A-INDUCED SENESCENCE 
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Bypassing cellular senescence, an irreversible growth arrest of cells that is 
activated in normal cells to become immortal is one of the prerequisites for cancer 
development. Cellular senescence can be triggered by shortening of telomeres and certain 
cellular stresses. Using spontaneously immortalized Li-Fraumeni Syndrome (LFS) 
fibroblasts, we found that CREG1 (Cellular Repressor of E1A-stimulated Genes1) is one 
of genes whose expression fit the criteria of senescence-associated genes, decreased 
expression during immortalization and increased in senescence. Moreover, we found that 
epigenetic mechanisms regulate CREG1 expression in LFS fibroblasts. CREG1 is a 
secreted glycoprotein that was shown to bind Rb-family pocket proteins and inhibit E2F 
transactivation activity. Therefore, we hypothesize that CREG1 plays a role in cellular 
senescence involving the p16INK4a-Rb pathway. Ectopic expression of CREG1 in the 
immortal LFS cell lines decreases cell proliferation but does not directly induce 
senescence. We confirmed this in osteosarcoma and fibrosarcoma cancer cell lines, 
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similar to those seen in patients with Li-Fraumeni Syndrome. Because CREG1 was 
shown to interact with Rb pocket proteins in vitro, we tested whether growth suppression 
by CREG1 may depend on the phosphorylation status of Rb. We found that p16INK4a, an 
inhibitor of CDK and Rb phosphorylation, is also downregulated in immortal cells and 
that coexpression of CREG1 and p16INK4a, has a greater effect than CREG1 or p16INK4a 
alone to reduce cell growth, to induce cell cycle arrest and cellular senescence in 
immortal LFS, osteosarcoma and fibrosarcoma cell lines. Moreover, cooperation of 
CREG1 and p16INK4a inhibits the expression of cyclin A and cyclin B by inhibiting 
promoter activity thereby decreasing mRNA and protein levels; these proteins are 
required for S-phase entry and G2/M transition. In conclusion, we are the first to find that 
CREG1 enhances p16INK4a–induced senescence by transcriptional repression of cell cycle 
mediated genes. 
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